Information Update - New lots recalled: Fresenius Medical Care continues recall of Sodium Bicarbonate Liquid Concentrate

Health Canada is updating Canadians and Canadian healthcare practitioners regarding Fresenius Medical Care's voluntary recall of "NaturaLyte Sodium Bicarbonate Liquid Concentrate" in 6.4L and 8L volumes due to bacterial contamination.

As of today, Health Canada has provided an update on all affected lots and posted advice for patients, hospitals and home patient programs.

Health Canada will continue monitoring the expanded recall and working with the company to help ensure patients and healthcare professionals are informed.

Fresenius Medical Care has indicated to Health Canada that it has shipped replacement product to customers and their patients.

Également disponible en français

SOURCE Health Canada

Latest Press Release on General News

Nicklaus Children's Health System, Philips to Provide Innovative Patient and Staff Experience, Helping to Enhance Outcomes for the Smallest of Patients

April 30, 2024 Philips AI-enabled diagnostic and experiential technologies help put patients at ease while empowering staff with faster, high-quality scans and increased diagnostic c...

Cinesteam® Is a Deodorizing Support Tool for Palliative Care

Palliative Care Is a Comprehensive Approach to Long-Term Patient Care. Caregivers Can Use Cinesteam®'s Secondary Dressings to Improve Quality of Life in Palliative Care Settings. FOR...

Philips Delivers First-quarter Results in Line With 2024 Performance Improvement Plan; Resolves the Respironics Personal Injury and Medical Monitoring Litigation in the Us for USD 1.1 Billion

April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4% Comparable order intake -3.8%, mainly due to China USD 1.1 b...

eNeura Achieves Record-Breaking Sales and Announces Notice of Allowance for a New Patent on Prophylactic Treatment of Migraine Headache

Record sales in April accelerating the pathway to profitability New IP will lead the way in changing the way migraine headaches are addressed WEST PALM BEACH, Fla. , April 26, ...

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...